Dr. Santos on the Potential Role for CEACAM5- and KEAP1-Targeted Therapies in NSCLC
Edgardo S. Santos, MD, discusses the potential role for CEACAM5- and KEAP1-targeted therapies in non–small cell lung cancer.
EP: 1.Dr. Gandara on Developments in HER2-Targeted Therapies in NSCLC
EP: 2.Dr. Gainor on the Potential Value of Targeting TROP-2 and CEACAM5 in Lung Cancer
EP: 3.Dr. Santos on the Potential Role for CEACAM5- and KEAP1-Targeted Therapies in NSCLC
EP: 4.Dr. Schenk on the Importance of Investigating Novel Targets in Lung Cancer
EP: 5.Dr. Skoulidis on the Rationale to Target TROP2 in Lung Cancer
Edgardo S. Santos, MD, clinical affiliate associate professor, Charles E. Schmidt College of Medicine, Florida Atlantic University, founding partner, Florida Precision Oncology, discusses the potential role for CEACAM5- and KEAP1-targeted therapies in non–small cell lung cancer (NSCLC).
CEACAM5 and KEAP1 are novel pathways under evaluation in NSCLC, says Santos. Targeted therapies directed toward these pathways have the potential to further evolve the treatment paradigm for this patient population.
Moreover, therapies targeting CEACAM5 and KEAP1 could offer potential strategies for patients with NSCLC who progress on chemotherapy or chemotherapy in combination with immunotherapy, Santos explains. The frontline setting for NSCLC is currently crowded with available options, but rescue options for patients who progress after frontline treatment are more limited, Santos concludes.
